Advertisement
U.S. markets closed
  • S&P 500

    5,254.35
    +5.86 (+0.11%)
     
  • Dow 30

    39,807.37
    +47.29 (+0.12%)
     
  • Nasdaq

    16,379.46
    -20.06 (-0.12%)
     
  • Russell 2000

    2,124.55
    +10.20 (+0.48%)
     
  • Crude Oil

    83.11
    -0.06 (-0.07%)
     
  • Gold

    2,254.80
    +16.40 (+0.73%)
     
  • Silver

    25.10
    +0.18 (+0.74%)
     
  • EUR/USD

    1.0794
    -0.0035 (-0.32%)
     
  • 10-Yr Bond

    4.2060
    +0.0100 (+0.24%)
     
  • GBP/USD

    1.2626
    -0.0012 (-0.09%)
     
  • USD/JPY

    151.4270
    +0.1810 (+0.12%)
     
  • Bitcoin USD

    71,001.03
    +1,767.96 (+2.55%)
     
  • CMC Crypto 200

    885.54
    0.00 (0.00%)
     
  • FTSE 100

    7,952.62
    +20.64 (+0.26%)
     
  • Nikkei 225

    40,168.07
    -594.66 (-1.46%)
     

Gilead to test inhaled version of remdesivir on COVID-19 patients in August

June 22 (Reuters) - Gilead Sciences Inc said on Monday that it plans to begin clinical trials of an inhaled version of its antiviral treatment remdesivir for COVID-19 patients in August.

The drug is currently used intravenously and an inhaled formulation would be given through a nebulizer, which could potentially allow for easier administration outside hospitals, the company said in a statement. (https://bit.ly/3eqpEJ9) (Reporting by Manas Mishra in Bengaluru; Editing by Arun Koyyur)

Advertisement